| Literature DB >> 28379698 |
Matthias Schiedel1, Daniel Herp1, Sören Hammelmann1, Sören Swyter1, Attila Lehotzky2, Dina Robaa3, Judit Oláh2, Judit Ovádi2, Wolfgang Sippl3, Manfred Jung1,4.
Abstract
Here we report the development of a proteolysis targeting chimera (PROTAC) based on the combination of the unique features of the sirtuin rearranging ligands (SirReals) as highly potent and isotype-selective Sirt2 inhibitors with thalidomide, a bona fide cereblon ligand. For the first time, we report the formation of a PROTAC by Cu(I)-catalyzed cycloaddition of a thalidomide-derived azide to an alkynylated inhibitor. This thalidomide-derived azide as well as the highly versatile linking strategy can be readily adapted to alkynylated ligands of other targets. In HeLa cells, our SirReal-based PROTAC induced isotype-selective Sirt2 degradation that results in the hyperacetylation of the microtubule network coupled with enhanced process elongation. Thus, our SirReal-based PROTAC is the first example of a probe that is able to chemically induce the degradation of an epigenetic eraser protein.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28379698 DOI: 10.1021/acs.jmedchem.6b01872
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446